October 14, 2019
Article
Novel β-lactam/β-lactamase inhibitor combinations and cefiderocol may play a part in the treatment of infections caused by Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex.
Fourth COVID-19 Vaccine Dose Boosts Immunity Above Third Shot
Estrogen Treatment Reduces Risk of COVID-19 Mortality
FDA Approves Pfizer-BioNTech Booster Shot for Children 5 and Older
An Issue About COVID-19